Navigation Links
Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Date:12/16/2008

PORTON DOWN, England and SAN FRANCISCO, Dec. 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed a term sheet for two patent license agreements with Roche Molecular Systems, Inc. (RMS).

The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and will allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing Enigma's existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and MRSA. These tests will be combined with Enigma's revolutionary and fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.

Financial terms were not disclosed.

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    212-827-0020
    Megan Dubrowski - Media
    mdubrowski@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK-based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralized and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
7. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
8. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
9. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
10. Quest Diagnostics Reports Third Quarter Results
11. ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology: